NERV
HEALTHCAREMinerva Neurosciences Inc
$6.23-0.02 (-0.32%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NERV Today?
No stock-specific AI insight has been generated for NERV yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.30$8.80
$6.23
Fundamentals
Market Cap$290M
P/E Ratio—
EPS$-37.03
Dividend Yield—
Dividend / Share—
ROE-6.8%
Profit Margin—
Debt / Equity—
Trading
Volume88K
Avg Volume (10D)—
Shares Outstanding46.6M
NERV News
20 articles- Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesYahoo Finance·May 5, 2026
- NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva NeurosciencesYahoo Finance·Apr 13, 2026
- Minerva Announces Leadership TransitionYahoo Finance·Apr 2, 2026
- Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of SchizophreniaYahoo Finance·Mar 31, 2026
- Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026Yahoo Finance·Mar 25, 2026
- Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia SymptomsMarketbeat·Mar 21, 2026
- Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS ForumYahoo Finance·Mar 12, 2026
- Minerva Neurosciences: Q4 Earnings SnapshotYahoo Finance·Mar 11, 2026
- Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business UpdatesYahoo Finance·Mar 11, 2026
- Minerva Neurosciences to Participate in The Citizens Life Sciences ConferenceYahoo Finance·Mar 4, 2026
- Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the mostYahoo Finance·Feb 16, 2026
- Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for SchizophreniaMarketbeat·Feb 4, 2026
- Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026Yahoo Finance·Jan 26, 2026
- Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of DirectorsYahoo Finance·Nov 19, 2025
- Minerva Neurosciences: Q3 Earnings SnapshotYahoo Finance·Nov 5, 2025
- Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business UpdatesYahoo Finance·Nov 5, 2025
- Top Midday GainersYahoo Finance·Oct 21, 2025
- BC-Most Active StocksYahoo Finance·Oct 21, 2025
- Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if ApprovedYahoo Finance·Oct 21, 2025
- Minerva Neurosciences: Q2 Earnings SnapshotYahoo Finance·Aug 14, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$6.25
Day High$0.00
Day Low$0.00
52 Week High$8.80
52 Week Low$1.30
52-Week Range
$1.30$8.80
$6.23
Fundamentals
Market Cap$290M
P/E Ratio—
EPS$-37.03
Dividend Yield—
Dividend / Share—
ROE-6.8%
Profit Margin—
Debt / Equity—
Trading
Volume88K
Avg Volume (10D)—
Shares Outstanding46.6M
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products for the treatment of diseases of the central nervous system. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—